Q4 2024 Bristol-Myers Squibb Co Earnings Call Transcript
Key Points
- Bristol-Myers Squibb Co (BMY) achieved double-digit revenue growth in 2024, driven by key products like BREYANZI, Krazati, Reblozyl, and Opdivo.
- The company successfully launched Cobenfy, a novel treatment for schizophrenia, marking a significant milestone in their neuroscience portfolio.
- Operational excellence and financial discipline led to significant cost savings, with $1.5 billion in savings targeted and most achieved in 2024.
- Bristol-Myers Squibb Co (BMY) accelerated several late-stage pipeline programs, including CEMZIOS and the ADEPT-2 study, ahead of schedule.
- The company has identified an additional $2 billion in savings, with $1 billion expected to be realized in 2025, enhancing financial flexibility.
- Bristol-Myers Squibb Co (BMY) faces near-term revenue impact due to generic competition across multiple products, including Revlimid and POMALYST.
- The company anticipates a decline in the legacy portfolio by 18% to 20% in 2025 due to loss of exclusivity and foreign exchange headwinds.
- Gross margin declined by 240 basis points in the fourth quarter of 2024, primarily due to product mix.
- The company is experiencing increased gross-to-net pressures from Medicare Part D redesign, impacting products like Eliquis.
- There are concerns about the potential impact of the Inflation Reduction Act (IRA) on pricing and market dynamics for key products.
Welcome to the Bristol-Myers Squibb fourth-quarter 2024 earnings conference call. (Operator instructions) Please note, this event is being recorded.
I would now like to turn the conference over to Chuck Triano, Senior Vice President and Head of Investor Relations. Please go ahead.
Thank you, and good morning, everyone. We appreciate you joining our fourth quarter 2024 earnings call. Joining me this morning with prepared remarks are Chris Boerner, our Board Chair and Chief Executive Officer; and David Elkins, our Chief Financial Officer. Also participating in today's call are Adam Lenkowsky, our Chief Commercialization Officer; and Summit Hirawat, our Chief Medical Officer and Head of Global Drug Development. Earlier this morning, we posted our quarterly slide presentation to bms.com that you can use to follow along with Chris and David's remarks.
Before we get started, I'll remind everybody that during this call, we will make statements about the company's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
